247 Patients Drive Actinogen’s Pending Alzheimer’s Results

Actinogen Medical’s shares have been suspended while it completes analysis of additional data from its pivotal XanaMIA Alzheimer’s trial. The company expects trading to resume no later than 19 November unless the results announcement comes first.

  • Immediate ASX suspension pending XanaMIA topline results
  • Additional clinical trial data received on 17 November
  • 247-patient phase 2b/3 trial testing Xanamem 10 mg
  • Primary endpoint is the CDR-SB dementia scale
  • Trading expected to resume by 19 November unless results come sooner
An image related to Actinogen Medical Limited A photo of the logo for Actinogen Medical Add us as a preferred source on Google
Image © middle. Logo © respective owner.

ASX Suspension Pending XanaMIA Results

Actinogen Medical Limited (ASX:ACW) has been suspended from trading as the biotech completes its analysis of additional clinical data from the pivotal XanaMIA phase 2b/3 Alzheimer’s disease trial. The company requested the voluntary suspension from the open on 17 November, and ASX granted it under Listing Rule 17.2.

Actinogen said the suspension is intended to remain in place until it releases the trial’s topline results, or until trading resumes on Thursday, 19 November, whichever comes first. The filing does not disclose whether XanaMIA met its primary endpoint, nor does it provide efficacy, safety or statistical results.

247-Patient Trial Tests Xanamem Against Placebo

XanaMIA is a double-blind, placebo-controlled 36-week study involving 247 patients with mild to moderate Alzheimer’s disease and progressive disease confirmed by elevated blood pTau181 levels. Participants received either once-daily Xanamem 10 mg or placebo, with the primary measure being change on the CDR-SB, an internationally recognised dementia-rating scale.

The suspension comes after a long-telegraphed clinical milestone. Actinogen had completed the final patient visit in September, a step covered in the final XanaMIA patient visit, and had continued to point to a November topline readout. The company has also said the trial passed an independent Data Monitoring Committee review for safety and efficacy futility, although that milestone does not establish whether the study ultimately demonstrated a treatment benefit.

Results Could Set the Next Development Path

For shareholders, the suspension marks the narrow window between data receipt and disclosure of a result capable of materially changing the company’s development plans and market valuation. Actinogen’s recent cash update left it with A$21.9 million in pro forma cash and no debt after an R&D tax rebate and repayment of an advance, giving the company funding visibility as it approaches the readout; however, the filing does not state how any XanaMIA outcome would affect financing or partnering plans.

Xanamem remains an investigational medicine and is not approved by the FDA or any other global regulatory authority. The next announcement will therefore need to do more than confirm a headline result: the market will have to assess the CDR-SB outcome, secondary endpoints, safety profile and statistical strength before judging what the data can support.

Get ASX:ACW news the moment it breaks

Instant push notifications No waitlist Free
Download on the App Store iPhone & iPad
Get it on Google Play Android
Email alerts

Bottom Line?

The suspension has put a firm date around Actinogen’s biggest clinical catalyst, but the filing offers no indication yet whether XanaMIA succeeded or failed.

Questions in the middle?

  • Did XanaMIA meet its CDR-SB primary endpoint, and by what margin?
  • What do the full efficacy and safety data show across the trial’s secondary measures?
  • Would the topline result change Actinogen’s funding, partnering or regulatory strategy?

Sources

1